Complement-Based Drug Development Summit leaderboard
  • Wednesday, September 30, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

17th World ADC San Diego Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 7

Author

Pharma Journalist 9091 posts 0 comments

AusperBio Raises $120 Million to Advance Hepatitis B Drug

Aug 31, 2026
AusperBio Therapeutics has raised $120 million in a Series C financing round to support the development of its experimental treatments for chronic hepatitis B (CHB) and prepare its lead…
Read More...

FDA Approves LISRAYA for Adults With Dermatomyositis

Aug 31, 2026
The U.S. Food and Drug Administration (FDA) has approved Priovant Therapeutics’ LISRAYA (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM), a rare autoimmune…
Read More...

FDA Approves Mounjaro to Reduce Cardiovascular Risk in Type 2 Diabetes

Aug 31, 2026
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at…
Read More...

Teva to Bid for BioXcel Assets in Chapter 11 Sale

Aug 31, 2026
BioXcel Therapeutics has entered into an agreement with Teva Pharmaceuticals International GmbH for the sale of substantially all of its assets as the biotechnology company begins…
Read More...

FDA Approves Tivicay PD for Infants With HIV

Aug 27, 2026
The U.S. Food and Drug Administration (FDA) has approved ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in children weighing at least 2 kg. The…
Read More...

FDA Grants Rare Pediatric Disease Designation to ReviR’s RTX-117

Aug 27, 2026
The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to ReviR Therapeutics’ investigational drug RTX-117 for the treatment of…
Read More...

FDA Approves Ziihera Combinations for HER2-Positive GEA

Aug 27, 2026
The U.S. Food and Drug Administration (FDA) has approved two Ziihera (zanidatamab-hrii)-based treatment regimens for the first-line treatment of adults with unresectable locally…
Read More...

FDA Approves RASONQUE for Metastatic Pancreatic Cancer

Aug 27, 2026
The U.S. Food and Drug Administration (FDA) has approved Revolution Medicines’ RASONQUE (daraxonrasib), a once-daily oral treatment for adults with metastatic pancreatic adenocarcinoma…
Read More...

REGENXBIO Delays RGX-121 Filing After Spine MRI Findings

Aug 25, 2026
REGENXBIO has provided an update on RGX-121, its investigational gene therapy for Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome. The company said it does not…
Read More...

Lundbeck Wins EU Orphan Designation for Cushing’s Syndrome Drug

Aug 25, 2026
Lundbeck has received orphan designation from the European Commission for asedebart (Lu AG13909), an experimental monoclonal antibody being developed to treat Cushing’s syndrome of…
Read More...
Prev Next
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Microbiome Movement USA Summit 2026
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Biomarker Operations & Biospecimen Management
2nd Obesity & Weight Loss Drug Development Summit Europe
RNA-Based Therapeutics & Vaccines Summit South Korea
RNA-Targeted Drug Discovery & Development Summit
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
10th IPF Summit
17th World ADC London
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Model-Informed Drug Development Summit 2026
IMPACCT Real-World Evidence Summit
Raw Materials for Cell & Gene Therapy Summit
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
17th World ADC San Diego
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Semaglutide 2 mg Linked to Lower Cardiovascular Risk in Diabetes
  • Novo Nordisk Licenses HRS-1596 for Weekly Oral GLP-1 Therapy
  • AbbVie’s Juvmo Wins FDA Approval for Parkinson’s Disease
  • Tolerance Bio Licenses TLB-33 to Expand Thymic Health Pipeline
  • Direct RNA Binding Emerges as a Powerful Approach for Functional Disease Modulation

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Direct RNA Binding Emerges as a Powerful Approach for…

AI, Structure Prediction and Advanced Computational Tools…

New Preclinical Data and Translational Advances Set to Take…

FDA, Health Canada & Leading Biopharma Organizations…

Industry Leaders Convene in Boston as Registration Remains…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.